Anti-asthmatic prescriptions in children with and without congenital anomalies: a European data linkage study.

Objectives Asthma is the most common chronic disease in childhood, yet little is known about rates of asthma and wheezing in children with congenital anomalies. This study explored the prevalence and risk of receiving anti-asthmatic prescriptions in children with congenital anomalies compared to chi...

Full description

Bibliographic Details
Main Authors: Natalie Divin, Ester Garne, Joan K Morris, Maria Loane
Format: Article
Language:English
Published: Swansea University 2022-08-01
Series:International Journal of Population Data Science
Subjects:
Online Access:https://ijpds.org/article/view/1889
_version_ 1797430689726988288
author Natalie Divin
Ester Garne
Joan K Morris
Maria Loane
author_facet Natalie Divin
Ester Garne
Joan K Morris
Maria Loane
author_sort Natalie Divin
collection DOAJ
description Objectives Asthma is the most common chronic disease in childhood, yet little is known about rates of asthma and wheezing in children with congenital anomalies. This study explored the prevalence and risk of receiving anti-asthmatic prescriptions in children with congenital anomalies compared to children without anomalies in six European regions/countries. Approach This was a EUROlinkCAT population-based linkage cohort study involving children from 0-9 years of age born between 2000-2014. Congenital anomaly data from six EUROCAT registries were linked to births data in national/vital statistics and to electronic prescription databases. Prescription/pharmacy dispensing records across regions were standardised to a Common Data Model. Anatomical Therapeutic Chemical classification codes beginning with R03 were used to identify anti-asthmatic prescriptions. Random-effects meta-analyses were performed to identify both the relative risk (RR) of receiving >1 anti-asthmatic prescription in a year relative to the reference group, and the heterogeneity of prevalence rates across registries and age group. Results A total of 5.1% of children with congenital anomalies and 4.9% of reference children were dropped from the study as they were not linked. Children with congenital anomalies (n=60,662) had a higher prevalence of >1 anti-asthmatic prescription and a significantly higher risk of being prescribed anti-asthmatics (RR=1.41, 95% CI 1.35-1.48) compared to reference children (n=1,722,912). The increased risk was consistent across all age groups. Children with congenital anomalies were more likely to be prescribed beta-2 agonists (RR=1.71, 95% CI 1.60-1.83) and inhaled corticosteroids (RR=1.74, 95% CI 1.61-1.87). Children with oesophageal atresia, diaphragmatic hernia, genetic syndromes and chromosomal anomalies had over twice the risk of being prescribed anti-asthmatics compared to reference children. Regional differences in prevalence and risk of anti-asthmatic prescriptions were identified. Conclusion Children aged <10 years with congenital anomalies consistently had higher prevalence and risk of receiving >1 anti-asthmatic prescription across age group and across European regions. This study demonstrates that information on the prevalence of anti-asthmatic prescriptions issued/dispensed can be obtained through data linkage to monitor changes in prevalence over time.
first_indexed 2024-03-09T09:31:12Z
format Article
id doaj.art-af3d4b2db5a94f7fafb4171f908013c5
institution Directory Open Access Journal
issn 2399-4908
language English
last_indexed 2024-03-09T09:31:12Z
publishDate 2022-08-01
publisher Swansea University
record_format Article
series International Journal of Population Data Science
spelling doaj.art-af3d4b2db5a94f7fafb4171f908013c52023-12-02T03:51:49ZengSwansea UniversityInternational Journal of Population Data Science2399-49082022-08-017310.23889/ijpds.v7i3.1889Anti-asthmatic prescriptions in children with and without congenital anomalies: a European data linkage study.Natalie Divin0Ester Garne1Joan K Morris2Maria Loane3Ulster UniversityPediatric Department, Hospital Lillebaelt KoldingSt George’s University of LondonSt George’s University of LondonObjectives Asthma is the most common chronic disease in childhood, yet little is known about rates of asthma and wheezing in children with congenital anomalies. This study explored the prevalence and risk of receiving anti-asthmatic prescriptions in children with congenital anomalies compared to children without anomalies in six European regions/countries. Approach This was a EUROlinkCAT population-based linkage cohort study involving children from 0-9 years of age born between 2000-2014. Congenital anomaly data from six EUROCAT registries were linked to births data in national/vital statistics and to electronic prescription databases. Prescription/pharmacy dispensing records across regions were standardised to a Common Data Model. Anatomical Therapeutic Chemical classification codes beginning with R03 were used to identify anti-asthmatic prescriptions. Random-effects meta-analyses were performed to identify both the relative risk (RR) of receiving >1 anti-asthmatic prescription in a year relative to the reference group, and the heterogeneity of prevalence rates across registries and age group. Results A total of 5.1% of children with congenital anomalies and 4.9% of reference children were dropped from the study as they were not linked. Children with congenital anomalies (n=60,662) had a higher prevalence of >1 anti-asthmatic prescription and a significantly higher risk of being prescribed anti-asthmatics (RR=1.41, 95% CI 1.35-1.48) compared to reference children (n=1,722,912). The increased risk was consistent across all age groups. Children with congenital anomalies were more likely to be prescribed beta-2 agonists (RR=1.71, 95% CI 1.60-1.83) and inhaled corticosteroids (RR=1.74, 95% CI 1.61-1.87). Children with oesophageal atresia, diaphragmatic hernia, genetic syndromes and chromosomal anomalies had over twice the risk of being prescribed anti-asthmatics compared to reference children. Regional differences in prevalence and risk of anti-asthmatic prescriptions were identified. Conclusion Children aged <10 years with congenital anomalies consistently had higher prevalence and risk of receiving >1 anti-asthmatic prescription across age group and across European regions. This study demonstrates that information on the prevalence of anti-asthmatic prescriptions issued/dispensed can be obtained through data linkage to monitor changes in prevalence over time. https://ijpds.org/article/view/1889Anti-asthmaticsPrescriptionsCongenital anomaliesPopulation-basedData linkagePharmaco-epidemiology
spellingShingle Natalie Divin
Ester Garne
Joan K Morris
Maria Loane
Anti-asthmatic prescriptions in children with and without congenital anomalies: a European data linkage study.
International Journal of Population Data Science
Anti-asthmatics
Prescriptions
Congenital anomalies
Population-based
Data linkage
Pharmaco-epidemiology
title Anti-asthmatic prescriptions in children with and without congenital anomalies: a European data linkage study.
title_full Anti-asthmatic prescriptions in children with and without congenital anomalies: a European data linkage study.
title_fullStr Anti-asthmatic prescriptions in children with and without congenital anomalies: a European data linkage study.
title_full_unstemmed Anti-asthmatic prescriptions in children with and without congenital anomalies: a European data linkage study.
title_short Anti-asthmatic prescriptions in children with and without congenital anomalies: a European data linkage study.
title_sort anti asthmatic prescriptions in children with and without congenital anomalies a european data linkage study
topic Anti-asthmatics
Prescriptions
Congenital anomalies
Population-based
Data linkage
Pharmaco-epidemiology
url https://ijpds.org/article/view/1889
work_keys_str_mv AT nataliedivin antiasthmaticprescriptionsinchildrenwithandwithoutcongenitalanomaliesaeuropeandatalinkagestudy
AT estergarne antiasthmaticprescriptionsinchildrenwithandwithoutcongenitalanomaliesaeuropeandatalinkagestudy
AT joankmorris antiasthmaticprescriptionsinchildrenwithandwithoutcongenitalanomaliesaeuropeandatalinkagestudy
AT marialoane antiasthmaticprescriptionsinchildrenwithandwithoutcongenitalanomaliesaeuropeandatalinkagestudy